Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Robert Borucki"'
Autor:
Priscilla M. Rosa‐Nieves, Robert Borucki, Corey Georgesen, Adam Sutton, Megan Arthur, Melodi Javid Whitley
Publikováno v:
Skin Health and Disease, Vol 3, Iss 5, Pp n/a-n/a (2023)
Abstract Trichodysplasia spinulosa (TS) is a rare disease that affects immunocompromised patients, characterized by hair‐like growths caused by TS‐associated polyomavirus infection. Little is known about specific immunosuppressive drugs that can
Externí odkaz:
https://doaj.org/article/0c2ebcfd489a4c6e942f1b51950745b2
Publikováno v:
JAAD Case Reports, Vol 26, Iss , Pp 95-97 (2022)
Externí odkaz:
https://doaj.org/article/d88846b2bc914d55866b527226087bd3
Publikováno v:
Lupus Science and Medicine, Vol 7, Iss 1 (2020)
Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic
Externí odkaz:
https://doaj.org/article/dad223e5c18c4157b0cbbad138a2c767
Autor:
Robert Borucki, MD, Josef Symon S. Concha, MD, Julie Burroughs, MA, Joyce Okawa, RN, Victoria P. Werth, MD
Publikováno v:
JAAD International, Vol 2, Iss , Pp 94-95 (2021)
Externí odkaz:
https://doaj.org/article/52bb2c2897534090a19865d0de8d14b4
Autor:
DeAnna Diaz, Thomas Vazquez, Victoria P. Werth, Robert Borucki, Emily Keyes, Rui Feng, Madison Grinnell
Publikováno v:
Journal of the American Academy of Dermatology. 87:418-419
Publikováno v:
Journal of clinical medicine. 11(10)
Bullous pemphigoid (BP) is a rare, chronic antibody-mediated autoimmune blistering disease primarily affecting the elderly, with an age of onset over 60. Current treatment options are limited and involve the use of corticosteroids and immunosuppressa
Autor:
Victoria P. Werth, Robert Borucki
Publikováno v:
Arthritis & Rheumatology. 72:1777-1785
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease that can present with a variety of skin manifestations and have a dramatic effect on a patient's quality of life. Effective treatment options for this disease are limited, and the ef
Autor:
Lisa N Guo, Lourdes M Perez-Chada, Robert Borucki, Vinod E Nambudiri, Victoria P Werth, Joseph F Merola
Publikováno v:
Lupus Science & Medicine
ObjectiveThe lack of standardised outcomes and outcome measures for cutaneous lupus erythematosus (CLE) represents a substantial barrier to clinical trial design, comparative analysis and approval of novel investigative treatments. We aimed to develo
Autor:
Rebecca G. Gaffney, Christina E. Bax, Emily Keyes, Victoria P. Werth, Robert Borucki, Steffan W. Schulz, Rui Feng, Josef Symon S. Concha, Joyce Okawa, D. Yan, Adarsh Ravishankar, Rebecca L Krain, Lisa Pappas-Taffer
Publikováno v:
Journal of the American Academy of Dermatology. 86:948-949
Publikováno v:
Current rheumatology reports. 22(10)
Understanding the pathogenesis of cutaneous lupus erythematosus (CLE) is an important step in developing new medications and providing effective treatment to patients. This review focuses on novel research within CLE pathogenesis, as well as some of